Phosphodiesterases as therapeutic targets
- 1 April 2003
- Vol. 61 (4) , 685-691
- https://doi.org/10.1016/s0090-4295(02)02439-1
Abstract
No abstract availableThis publication has 43 references indexed in Scilit:
- The New Phosphodiesterase 4 Inhibitor Roflumilast Is Efficacious in Exercise‐Induced Asthma and Leads to Suppression of LPS‐Stimulated TNF‐α Ex VivoThe Journal of Clinical Pharmacology, 2002
- Human PDE5A gene encodes three PDE5 isoforms from two alternate promotersInternational Journal Of Impotence Research, 2002
- The Sequence of the Human GenomeScience, 2001
- EXPRESSION OF DIFFERENT PHOSPHODIESTERASE GENES IN HUMAN CAVERNOUS SMOOTH MUSCLEJournal of Urology, 2001
- Cyclic-3′,5′-nucleotide phosphodiesterase isozymes in cell biology and pathophysiology of the kidneyKidney International, 1999
- EFFECT OF THE SELECTIVE PHOSPHODIESTERASE TYPE 5 INHIBITOR SILDENAFIL ON ERECTILE FUNCTION IN THE ANESTHETIZED DOGJournal of Urology, 1998
- Antisense Inhibition of Phosphodiesterase ExpressionMethods, 1998
- Zaprinast accelerates recovery from established acute renal failure in the ratKidney International, 1995
- On the medical history of xanthines and other remedies for asthma: a tribute to HH Salter.Thorax, 1985
- THE PROPERTIES OF AN ADENINE RIBONUCLEOTIDE PRODUCED WITH CELLULAR PARTICLES, ATP, Mg++, AND EPINEPHRINE OR GLUCAGONJournal of the American Chemical Society, 1957